Orthofix Q3 2026 Earnings Call - ORTHOFIX MEDICAL INC

Financial Performance:

• Reported Q3 2026 net sales of $207.9 million, a 2.3% year-over-year increase on a pro forma constant currency basis (excluding discontinued M6 lines).
• Global spine net sales reached $107.4 million, down ~1% YoY; US spine fixation declined 5% due to market softness and distributor constraints, while global spine fixation grew 1% on a constant currency basis.
• Biologics sales were roughly flat sequentially despite seasonal softness, with positive YoY growth returning in October.
• Therapeutic Solutions generated $64 million in sales (+4% YoY) with strong margins and cash generation.
• Global Limb Reconstruction reported $36.4 million in sales (+9% YoY), driven by >20% growth in FitBone and TRULOC Elevate platforms.
• Non-GAAP adjusted gross margin stood at 70.7%, reflecting unfavorable geographic mix.
• EBITDA was $26.0 million (12.5% of pro forma net sales), up from $24.6 million (12.1%) in the prior year, driven by cost discipline offsetting lower revenue leverage.
• Ended the quarter with $86.9 million in cash, cash equivalents, and restricted cash; working capital changes reflected instrument set investments for Virada launch and European MDR inventory buildup.

Guidance and Future Outlook:

• Updated full-year 2026 pro forma net sales guidance to $825 million–$830 million, down from previous expectations due to spine market softness, supplier delays, and FX headwinds.
• Updated full-year 2026 non-GAAP EBITDA guidance to $86 million–$88 million.
• Q4 outlook includes sequential growth driven by normal seasonality and ~$15 million in net sales recognition from the European Distributor Arrangement (though creating a temporary free cash timing headwind in 2026).
• 2027 outlook anticipates an ~$22 million net sales headwind related to European MDR (medical device regulation) compliance completion.
• Excluding the MDR headwind, core revenue is expected to show positive growth in 2027; the Virada spinal implant system is scheduled for full market launch in Q4 2026.
• No specific 2027 financial guidance or long-term financial targets were provided at this time, though management expects spine revenue to stabilize post-transition.

Business Segments and Product Lines:

• US Spine: Undergoing portfolio simplification and distributor network consolidation; 80% of revenue now concentrated in core partners. Exiting lower-performing relationships to redeploy assets to high-value technology.
• Virada: The new spinal implant system for open procedures is on track for Q4 2026 launch; management expects this to drive significant growth in 2027.
• 7D Navigation: Received two 510K clearances in Q3 for software enhancements; system continues to gain customer traction and optimize workflow.
• Limb Reconstruction: TRULOC Elevate system received a 510K pre-market notification for an automated version in September; pursuing additional indications such as diabetic foot ulcers.
• Biologics: Stabilizing in the US; prioritizing account execution and utilization of OsteoCov products to drive growth.
• Therapeutic Solutions: Utilizing digital tools (AXEL STEAM 2.0, STEAM OnTrack) to improve prescription conversion and physician engagement.

Market and Competitive Landscape:

• US spine market experienced unexpected procedural softness, impacting even top-tier customers.
• Core distributors are still growing above the market rate, suggesting the company is retaining share despite temporary supply disruptions.
• Limb Reconstruction franchise is expanding into underserved markets, with international demand showing strength.
• European MDR requirements are creating a temporary regulatory-driven timing impact on revenue recognition but not underlying demand.

Risks and Challenges:

• Supply Chain: Unplanned supplier delays (specifically in instrument manufacturing and inter-bodies) caused inventory and instrument set constraints, impacting Q3 execution.
• Market Dynamics: Softness in US spine procedural volume and weaker growth among non-core distributors.
• Regulatory: European MDR compliance is expected to create a significant $22 million net sales headwind in 2027.
• Transition Risks: Consolidating the distributor network and exiting non-strategic partners creates short-term disruption in revenue and channel productivity.
• Foreign Exchange: Currency headwinds impacted reported figures and future outlooks.

Management Commentary and Tone:

• Management acknowledged Q3 results were below expectations but emphasized a "clear recovery plan" and disciplined execution.
• Tone was cautious yet confident regarding the long-term strategy, characterizing current headwinds as temporary and fixable.
• Leadership stressed a shift toward focusing resources on the top 20% of distributors and highest-value technologies.
• Emphasis placed on stabilizing the US spine business while maintaining momentum in Limb Reconstruction and Therapeutic Solutions.

Analyst Questions and Answers:

• Market Softness vs. Share Loss: Management clarified that the decline is primarily due to market softness in procedural volume and supply delays, not significant market share loss among core accounts.
• Distributor Network: Confirmed that core distributors grew in the mid-single digits (slower than prior rates) due to supply issues, but the strategy to consolidate the network remains unchanged.
• 2027 Revenue: Excluding the MDR headwind, core revenue growth is expected to be positive in 2027; Q4 2026 performance will be a reasonable proxy for the 2027 run rate.
• Supplier Delays: Confirmed as concentrated in inter-body instrument manufacturing; fixes are underway with expected resolution by end of Q4.
• Financial Targets: Management did not commit to releasing long-range financial targets alongside 2027 guidance, stating it depends on progress in the coming months.

Other Key Points:

• An earn-out customer continues to exceed contracted purchase commitments for spinal hardware and biologics.
• The European Distributor Arrangement creates a temporary mismatch in cash flows (cash outflows in 2026, receipts in 2027) which does not alter the view of underlying earnings power.
• Management reiterated the exit of non-strategic distributors represents only 20% of the business, with the remaining 80% now concentrated in core partners.
• The company is investing in innovation, including the automated TRULOC Elevate and expanding 7D navigation capabilities.